Overall, these results suggest that the genetic inhibition of mPTP in the CPVT model of CASQ2 KO did not lead to overt pathological cardiac remodeling, despite some early signs of potential cardiac hypertrophy. The gene discussed is CASQ2; the disease is cardiac hypertrophy.